226 related articles for article (PubMed ID: 36206989)
21. Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction: Pharmacology and Clinical Impact of the Sildenafil Citrate Orodispersible Tablet Formulation.
Scaglione F; Donde S; Hassan TA; Jannini EA
Clin Ther; 2017 Feb; 39(2):370-377. PubMed ID: 28139291
[TBL] [Abstract][Full Text] [Related]
22. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
[TBL] [Abstract][Full Text] [Related]
23. Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
Rosen RC; Kostis JB
Am J Cardiol; 2003 Nov; 92(9A):9M-18M. PubMed ID: 14609619
[TBL] [Abstract][Full Text] [Related]
24. Effect of sildenafil on platelet function and platelet cGMP of patients with erectile dysfunction.
Akand M; Gencer E; Yaman Ö; Erişgen G; Tekin D; Özdiler E
Andrologia; 2015 Dec; 47(10):1098-102. PubMed ID: 25486996
[TBL] [Abstract][Full Text] [Related]
25. Phosphodiesterase 5 inhibitors as novel agents for the treatment of Alzheimer's disease.
Liu L; Xu H; Ding S; Wang D; Song G; Huang X
Brain Res Bull; 2019 Nov; 153():223-231. PubMed ID: 31493542
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular effects of phosphodiesterase type 5 inhibitors.
Vlachopoulos C; Ioakeimidis N; Rokkas K; Stefanadis C
J Sex Med; 2009 Mar; 6(3):658-74. PubMed ID: 19138362
[TBL] [Abstract][Full Text] [Related]
27. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
28. Pharmacologic therapy for erectile dysfunction and its interaction with the cardiovascular system.
Ioakeimidis N; Kostis JB
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):53-64. PubMed ID: 24281316
[TBL] [Abstract][Full Text] [Related]
29. [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction].
Liu Y
Zhonghua Nan Ke Xue; 2013 Dec; 19(12):1147-51. PubMed ID: 24432631
[TBL] [Abstract][Full Text] [Related]
30. Resveratrol and sildenafil synergistically improve diabetes-associated erectile dysfunction in streptozotocin-induced diabetic rats.
Bai Y; An R
Life Sci; 2015 Aug; 135():43-8. PubMed ID: 26006044
[TBL] [Abstract][Full Text] [Related]
31. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
33. Off-Target Effect of Sildenafil on Postsurgical Erectile Dysfunction: Alternate Pathways and Localized Delivery System.
Salmasi A; Lee GT; Patel N; Goyal R; Dinizo M; Kwon YS; Modi PK; Faiena I; Kim HJ; Lee N; Hannan JL; Kohn J; Kim IY
J Sex Med; 2016 Dec; 13(12):1834-1843. PubMed ID: 27843073
[TBL] [Abstract][Full Text] [Related]
34. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
35. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
36. Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.
Percival JM; Whitehead NP; Adams ME; Adamo CM; Beavo JA; Froehner SC
J Pathol; 2012 Sep; 228(1):77-87. PubMed ID: 22653783
[TBL] [Abstract][Full Text] [Related]
37. The role of nitric oxide in erectile dysfunction: implications for medical therapy.
Burnett AL
J Clin Hypertens (Greenwich); 2006 Dec; 8(12 Suppl 4):53-62. PubMed ID: 17170606
[TBL] [Abstract][Full Text] [Related]
38. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Herlemann A; Gratzke C; Andersson KE; Sievert KD
Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
40. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
Wallis RM; Corbin JD; Francis SH; Ellis P
Am J Cardiol; 1999 Mar; 83(5A):3C-12C. PubMed ID: 10078537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
